As the one-year anniversary of the passage of The Family Smoking Prevention and Tobacco Control Act neared, this event provided a thought-provoking, forward-looking discussion of the law, the programmatic and regulatory landscape and the impact of modified risk products on tobacco.

Panelists examined what happens when a deadly product - tobacco - morphs into technical compliance; how the US Food and Drug Administration can maximize the opportunities that lie ahead and the myths and misperceptions of having FDA-regulated tobacco products.  

Our panel of experts identified the markers for success over the course of the next five years as public health leaders work to reduce the number one preventable cause of death in the nation. 

Opening Remarks by Legacy’s Immediate Past President and CEO, Cheryl Healton, Dr.PH.